EUVIMEDEUVIMED entdecken
Crossref

Bayesian optimal phase II designs with dual‐criterion decision making

Yujie Zhao, Daniel Li, Rong Liu, Ying Yuan iD

Pharmaceutical Statistics · 2023

DOI: 10.1002/pst.2296 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceutical Statistics, 2023. Verfasst von Yujie Zhao und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. Hauptthemen laut MEDLINE: Decision Making, Research Design. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 30 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The conventional phase II trial design paradigm is to make the go/no‐go decision based on the hypothesis testing framework. Statistical significance itself alone, however, may not be sufficient to establish that the drug is clinically effective enough to warrant confirmatory phase III trials. We propose the Bayesian optimal phase II trial design with dual‐criterion decision making (BOP2‐DC), which incorporates both statistical significance and clinical relevance into decision making. Based on the posterior probability that the treatment effect reaches the lower reference value (statistical significance) and the clinically meaningful value (clinical significance), BOP2‐DC allows for go/consider/no‐go decisions, rather than a binary go/no‐go decision. BOP2‐DC is highly flexible and accommodates various types of endpoints, including binary, continuous, time‐to‐event, multiple, and coprimary endpoints, in single‐arm and randomized trials. The decision rule of BOP2‐DC is optimized to maximize the probability of a go decision when the treatment is effective or minimize the expected sample size when the treatment is futile. Simulation studies show that the BOP2‐DC design yields desirable operating characteristics. The software to implement BOP2‐DC is freely available at www.trialdesign.org .

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Decision MakingResearch DesignHumansBayes TheoremComputer SimulationSample SizeClinical Trials, Phase II as Topic

Stichwörter der Autor:innen

Bayesian adaptive designgo/consider/no-go decisionoptimal designphase II trials

Autor:innen und Institutionen

  • Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Global Biometrics and Data Sciences, Bristol Myers Squibb, Berkeley Heights, New Jersey, USA.

ORCID-Profile: Ying Yuan

Zitieren

APA

Zhao, Y., Li, D., Liu, R., & Yuan, Y. (2023). Bayesian optimal phase II designs with dual‐criterion decision making. Pharmaceutical Statistics. https://doi.org/10.1002/pst.2296

Vancouver

Zhao Y, Li D, Liu R, Yuan Y. Bayesian optimal phase II designs with dual‐criterion decision making. Pharmaceutical Statistics. 2023. doi:10.1002/pst.2296

BibTeX
@article{Zhao2023,
  author = {Zhao, Yujie and Li, Daniel and Liu, Rong and Yuan, Ying},
  title = {Bayesian optimal phase II designs with dual‐criterion decision making},
  journal = {Pharmaceutical Statistics},
  year = {2023},
  doi = {10.1002/pst.2296}
}
Kostenlos starten →